Reliance’s Tira launches South Korean dermo‑cosmetic brand Dr. Melaxin in India

Reliance Retail’s digital beauty hub, Tira, has just opened the doors for a new player in India’s fast‑growing skin‑care arena – South Korean dermo‑cosmetic label Dr. Melaxin. The partnership means that, for the first time, Indian shoppers can snag the Korean line through Tira’s e‑commerce portal and a handful of its flagship stores.

What makes Dr. Melaxin stand out? The brand says its formulations draw inspiration from vaccine science – a bit of a buzz‑word that signals rigorous R&D – and every product is put through dermatologist testing, especially for sensitive skin. The range tackles the usual suspects – stubborn pigmentation, enlarged pores, loss of firmness and the inevitable signs of ageing – in what the company calls “clinical‑grade” formats.

Over the past few years, dermo‑cosmetics have crept out of hospitals and into the mainstream. They sit in that sweet spot between prescription‑only dermatology creams and the everyday moisturisers you see on every shelf. Consumers are getting savvier; a quick online search now reveals ingredients such as retinol, niacinamide, ceramides and peptides before they even step into a clinic. “People want proof, they want data, not just pretty packaging,” notes Dr. Deepali Bhardwaj, a senior dermatologist at Max Hospital, Saket.

And the numbers back that up. Euromonitor International reported that India’s skin‑care market swelled by 13 % in 2025, hitting roughly ₹32,210 crore. A big chunk of that growth is being driven by products that promise clinical efficacy and ingredient transparency – exactly the space Dr. Melaxin aims to occupy.

Indian pharma players are feeling the heat, too. Glenmark, for instance, highlighted in its FY25 report that its consumer‑care division is rapidly carving out a niche in the dermatology‑led self‑care segment, rolling out brands like Episoft AC and La Shield. The trend is clear: the line between medicine and beauty is blurring, and brands that can back their claims with science are winning the consumer’s trust.

Speaking on the launch, Yu Kyoung Hwa, CEO of Dr. Melaxin, said, “Indian buyers are curious, they read up on ingredients, and they care about long‑term skin resilience. Our Peel Shot series, for example, is designed to address pigmentation and texture while supporting the skin’s natural barrier.” He added that the partnership with Tira will help the brand reach the right audience – those who hunt for evidence‑based solutions rather than just hype.

For Tira, the addition of Dr. Melaxin broadens an already eclectic portfolio that includes other international names. The retailer hopes the collaboration will not only enrich its premium offering but also cement its reputation as a go‑to destination for science‑driven beauty.

So, whether you’re a dermatologist looking for a clinic‑friendly product, a beauty‑enthusiast hunting for that next‑level serum, or just someone who’s tired of vague promises, the Dr. Melaxin launch might be worth a click. After all, in a market that’s getting increasingly sophisticated, a little extra science never hurts.